Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants
Open Access
- 4 July 2022
- journal article
- research article
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (8) , e15230
Abstract
The recent emergence of multiple SARS‐CoV‐2 variants has caused considerable concern due to both reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is, therefore, paramount to develop therapeutic strategies that inhibit all known and future SARS‐CoV‐2 variants. Here, we report that all SARS‐CoV‐2 variants analyzed, including variants of concern (VOC) Alpha, Beta, Gamma, Delta, and Omicron, exhibit enhanced binding affinity to clinical grade and phase 2 tested recombinant human soluble ACE2 (APN01). Importantly, soluble ACE2 neutralized infection of VeroE6 cells and human lung epithelial cells by all current VOC strains with markedly enhanced potency when compared to reference SARS‐CoV‐2 isolates. Effective inhibition of infections with SARS‐CoV‐2 variants was validated and confirmed in two independent laboratories. These data show that SARS‐CoV‐2 variants that have emerged around the world, including current VOC and several variants of interest, can be inhibited by soluble ACE2, providing proof of principle of a pan‐SARS‐CoV‐2 therapeutic.Keywords
Funding Information
- Austrian Science Fund (Z 271‐B19)
- Canada 150 Chair (F18‐01336)
- Center for Strategic Scientific Initiatives, National Cancer Institute (75N91019D00024)
- Center for Strategic Scientific Initiatives, National Cancer Institute (75N91019F00130)
- Canadian Institutes of Health Research (F20‐02343)
- Canadian Institutes of Health Research (F20‐02015)
- Innovative Medicines Initiative (101005026)
- T. von Zastrow foundation Swiss National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P400PM_194473)
This publication has 63 references indexed in Scilit:
- Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2Cell, 2020
- Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2Cell, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Structural basis of receptor recognition by SARS-CoV-2Nature, 2020
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- Inhibition of Ebola Virus by a Molecularly Engineered Banana LectinPLOS Neglected Tropical Diseases, 2019
- Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human SubjectsClinical Pharmacokinetics, 2013
- Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transportersPharmacology & Therapeutics, 2010
- Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in pigletsCritical Care Medicine, 2010
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005